Sorafenib Tosylate With or Without Everolimus in Treating Patients With Advanced, Radioactive Iodine Refractory Hurthle Cell Thyroid Cancer



Status:Recruiting
Conditions:Endocrine
Therapuetic Areas:Endocrinology
Healthy:No
Age Range:18 - Any
Updated:3/7/2019
Start Date:October 2014
Contact:Eric Sherman, M.D.
Phone:646 888-4234

Use our guide to learn which trials are right for you!

Randomized Phase II Study of Sorafenib With or Without Everolimus in Patients With Radioactive Iodine Refractory Hurthle Cell Thyroid Cancer

This randomized phase II trial studies the effects, good and bad, of using everolimus along
with sorafenib tosylate versus sorafenib tosylate alone in treating patients with advanced
radioactive iodine refractory thyroid cancer. Sorafenib tosylate and everolimus may stop the
growth of tumor cells by blocking some of the enzymes needed for cell growth. The addition of
everolimus to sorafenib tosylate may cause more shrinkage of thyroid cancer and may prevent
it from growing but it could also cause more side effects than sorafenib tosylate alone. It
is not yet known whether this treatment with sorafenib tosylate and everolimus is better, the
same, or worse than sorafenib tosylate alone.

This randomized Phase II trial will compare the progression-free survival (PFS) of sorafenib
and everolimus versus sorafenib alone in patients with radioactive iodine refractory hurthle
cell thyroid cancer. Prior studies have shown that the median PFS is generally around 4.5
months for sorafenib alone in this disease population. It is hoped that the combination of
everolimus and sorafenib can increase the median PFS to at least 9 months. In addition to
PFS, this trial will also compare the confirmed response rate, overall survival (OS) and
adverse event rates between sorafenib and everolimus vs. sorafenib alone. The primary and
secondary objectives for the study are listed below.

Primary Objective:

To compare the progression free survival between sorafenib and everolimus versus sorafenib
alone in patients with radioactive iodine refractory Hurthle cell thyroid cancer

Secondary Objective:

To compare the confirmed response rate, overall survival and adverse event rates between
sorafenib and everolimus versus sorafenib alone.

Treatment will continue until disease progression or unacceptable adverse events. Patients
will be followed for 5 years after randomization.

Eligibility Criteria:

1. Central pathology review submission - Patients must have 10 representative hematoxylin
and eosin (H&E) stained thyroid tissue slides OR tumor block available for submission
to central pathology review. This review is mandatory prior to registration to confirm
eligibility.

2. Measurable disease - Patients must have measurable disease by Response Evaluation
Criteria In Solid Tumors (RECIST) criteria, defined as at least one lesion that can be
accurately measured in at least one dimension (longest diameter to be recorded) as ≥
20 mm with conventional techniques or as ≥ 10 mm with spiral computed tomography (CT)
scan. CT must be performed within 28 days of registration.

3. Radioactive iodine (RAI) - refractory disease defined as 1 or more of the following:

- Patients who have received greater than 600 mCi of radioactive iodine in their
lifetime OR

- RAI-avid metastatic lesion which remained stable in size or progressed despite
RAI treatment within 9 months of RAI treatment OR

- 10% or more increase in serum thyroglobulin (on thyroid-stimulating hormone
[TSH]-suppression) within 9 months of RAI treatment OR

- Index metastatic lesion non-RAI avid on a diagnostic RAI scan OR

- Presence of fluorodeoxyglucose (FDG) avid metastatic lesions on positron emission
tomography (PET)/CT scan (standardized uptake values [SUV]max > 5 of any single
lesion)

4. Progressive disease defined by RECIST criteria ≤ 14 months

5. Patients must have metastatic disease or locally advanced unresectable disease

6. Prior treatment

- Patients may have received prior radiation therapy to index lesions ≥ 28 days
prior to registration on this protocol if there has been documented progression
by RECIST criteria. Prior radiation therapy to the non-index lesions is allowed
if ≥ 28 days prior to registration on this protocol.

- Prior RAI therapy is allowed if ≥ 90 days prior to registration on this protocol
and evidence of progression (as defined above) has been documented in the interim
(a diagnostic study using < 10 mCi of RAI is not considered RAI therapy).

- Prior chemotherapy is allowed if ≥ 28 days prior to registration on this
protocol.

- Patient may have received any number of prior lines of therapy.

- No prior use of sorafenib or an mammalian target of rapamycin (mTOR) (including
phosphoinositide 3-kinase [PI3k] or protein kinase B [AKT]) inhibitor for the
treatment of thyroid cancer.

7. No history of major surgery ≤ 28 days of registration

8. No history of intracranial brain metastasis

9. Cardiovascular disease. No history of any of the following ≤ 6 months of registration:

- Myocardial infarction or unstable angina

- New York Heart Association grade III or greater congestive heart failure

- Cerebrovascular accident

- Grade 3 or 4 peripheral ischemia

- Grade 3 or 4 thromboembolic event

10. Liver disease: No history of the following:

- Child Pugh Class B or C liver disease

- "Chronic active" hepatitis defined as:

1. Hepatitis B surface antigen (HBsAg) > 6 months

2. Serum hepatitis B virus (HBV) deoxyribonucleic acid (DNA) 20,000 IU/ml (105
copies/ml), lower values 2,000-20,000 IU/ml (104-105 copies/ml) are often
seen in hepatitis B e antigen (HBeAg)-negative chronic hepatitis B

3. Persistent or intermittent elevation in alanine aminotransferase
(ALT)/aspartate aminotransferase (AST) levels

4. Liver biopsy showing chronic hepatitis with moderate or severe
necroinflammation

11. No history of gastrointestinal fistula or gastrointestinal perforation < 90 days of
registration.

12. No known history of prolonged QT syndrome

13. No Grade 3 or 4 hypertension (systolic blood pressure [BP] >160 and or diastolic BP >
100) that cannot be controlled with medication prior to registration.

14. Concomitant medications:

- Chronic concomitant treatment with strong inhibitors of cytochrome P450 3A4
(CYP3A4) is not allowed on this study. Patients on strong CYP3A4 inhibitors must
discontinue the drug for 14 days prior to registration on the study.

- Chronic concomitant treatment with strong CYP3A4 inducers is not allowed.
Patients must discontinue the drug 14 days prior to the start of study treatment.

- Patients requiring anticoagulation must be on stable dose of medication prior to
registration.

15. Not pregnant and not nursing, because this study involves an investigational agent
whose genotoxic, mutagenic and teratogenic effects on the developing fetus and newborn
are unknown. Therefore, for women of childbearing potential only, a negative serum
pregnancy test done ≤ 7 days prior to registration is required.

16. Age ≥ 18 years

17. Eastern Cooperative Oncology Group (ECOG) Performance Status ≤ 2

18. Required Initial Laboratory Values:

- Absolute neutrophil count (ANC) ≥ 1,500/mm^3

- Platelet count ≥ 100,000/mm^3

- Creatinine ≤ 1.5 mg/dL OR

- Calculated creatinine clearance ≥ 30 mL/min

- Total bilirubin ≤ 1.5 x upper limits of normal (ULN)

- Serum glutamic oxaloacetic transaminase (SGOT) (AST) ≤ 2.5 x ULN

- Fasting serum cholesterol ≤ 300 mg/dL

19. Documentation of disease: Histologic Documentation - Eligible patients must have
histopathologically confirmed Hürthle cell thyroid cancer by central review.
We found this trial at
22
sites
Basking Ridge, New Jersey 07920
Principal Investigator: Eric J. Sherman
Phone: 212-639-5007
?
mi
from
Basking Ridge, NJ
Click here to add this to my saved trials
1500 East Medical Center Drive
Ann Arbor, Michigan 48109
800-865-1125
Principal Investigator: Francis P. Worden
University of Michigan Comprehensive Cancer Center The U-M Comprehensive Cancer Center's mission is the conquest...
?
mi
from
Ann Arbor, MI
Click here to add this to my saved trials
303 East Superior Street
Chicago, Illinois 60611
Principal Investigator: Maria Matsangou
Phone: 312-695-1301
?
mi
from
Chicago, IL
Click here to add this to my saved trials
Clinton, North Carolina 28328
Principal Investigator: James N. Atkins
Phone: 919-587-9077
?
mi
from
Clinton, NC
Click here to add this to my saved trials
Columbus, Ohio 43210
Principal Investigator: Bhavana Konda
Phone: 800-293-5066
?
mi
from
Columbus, OH
Click here to add this to my saved trials
Commack, New York 11725
Principal Investigator: Eric J. Sherman
Phone: 631-623-4000
?
mi
from
Commack, NY
Click here to add this to my saved trials
Goldsboro, North Carolina 27534
Principal Investigator: James N. Atkins
Phone: 919-587-9077
?
mi
from
Goldsboro, NC
Click here to add this to my saved trials
2700 Wayne Memorial Dr
Goldsboro, North Carolina 27534
(919) 736-1110
Principal Investigator: James N. Atkins
Phone: 919-731-6687
Wayne Memorial Hospital Wayne Memorial Hospital, an affiliate of Wayne Health Corporation, is home to...
?
mi
from
Goldsboro, NC
Click here to add this to my saved trials
500 Westchester Avenue
Harrison, New York 10604
Principal Investigator: Eric J. Sherman
Phone: 212-639-7592
?
mi
from
Harrison, NY
Click here to add this to my saved trials
4500 San Pablo Rd S
Jacksonville, Florida 32224
(904) 953-2000
Principal Investigator: Ashish V. Chintakuntlawar
Phone: 855-776-0015
Mayo Clinic Florida Thousands of people come to Mayo Clinic in Jacksonville, Fla., annually for...
?
mi
from
Jacksonville, FL
Click here to add this to my saved trials
Jacksonville, North Carolina 28546
Principal Investigator: James N. Atkins
Phone: 910-353-0824
?
mi
from
Jacksonville, NC
Click here to add this to my saved trials
Janesville, Wisconsin 53547
Principal Investigator: Emily G. Robinson
Phone: 800-928-1103
?
mi
from
Janesville, WI
Click here to add this to my saved trials
Middletown, New Jersey 07748
Principal Investigator: Eric J. Sherman
Phone: 212-639-7592
?
mi
from
Middletown, NJ
Click here to add this to my saved trials
225 Summit Avenue
Montvale, New Jersey 07645
Principal Investigator: Eric J. Sherman
Phone: 212-639-7592
?
mi
from
Montvale, NJ
Click here to add this to my saved trials
1275 York Ave
New York, New York 10021
(212) 639-2000
Principal Investigator: Eric J. Sherman
Phone: 212-639-7592
Memorial Sloan Kettering Cancer Center Memorial Sloan Kettering Cancer Center — the world's oldest and...
?
mi
from
New York, NY
Click here to add this to my saved trials
8303 Dodge Street
Omaha, Nebraska 68114
(402) 354–4000
Principal Investigator: Yungpo B. Su
Phone: 402-354-5144
Nebraska Methodist Hospital Methodist Hospital is a general medical and surgical hospital in Omaha, NE....
?
mi
from
Omaha, NE
Click here to add this to my saved trials
Philadelphia, Pennsylvania 19111
Principal Investigator: Jessica R. Bauman
Phone: 215-728-4790
?
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Rochester, Minnesota 55905
Principal Investigator: Ashish V. Chintakuntlawar
Phone: 855-776-0015
?
mi
from
Rochester, MN
Click here to add this to my saved trials
Rockville Centre, New York 11570
Principal Investigator: Eric J. Sherman
Phone: 516-256-3651
?
mi
from
Rockville Centre, NY
Click here to add this to my saved trials
Sioux City, Iowa 51101
Principal Investigator: Donald B. Wender
Phone: 712-252-9326
?
mi
from
Sioux City, IA
Click here to add this to my saved trials
777 Broadway
Sleepy Hollow, New York 10591
?
mi
from
Sleepy Hollow, NY
Click here to add this to my saved trials
Wilson, North Carolina 27893
Principal Investigator: James N. Atkins
Phone: 919-580-0000
?
mi
from
Wilson, NC
Click here to add this to my saved trials